These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 23963888)

  • 1. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2016 Jun; 91(6):631-42. PubMed ID: 27185207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2018 Jun; 93(6):824-840. PubMed ID: 29878489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2020 Jan; 95(1):97-115. PubMed ID: 31736132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
    Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
    Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2022 Mar; 97(3):352-372. PubMed ID: 34985762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses on clinical characteristic and prognoses of 41 patients with chronic myelomonocytic leukemia in China.
    Chen B; Ma Y; Xu X; Wang X; Qin W; Ji M; Lin G
    Leuk Res; 2010 Apr; 34(4):458-62. PubMed ID: 19631982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.
    Adès L; Sekeres MA; Wolfromm A; Teichman ML; Tiu RV; Itzykson R; Maciejewski JP; Dreyfus F; List AF; Fenaux P; Komrokji RS
    Leuk Res; 2013 Jun; 37(6):609-13. PubMed ID: 23415110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.
    McCullough KB; Patnaik MM
    Curr Hematol Malig Rep; 2015 Sep; 10(3):292-302. PubMed ID: 26122388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current management of patients with chronic myelomonocytic leukemia.
    Alfonso A; Montalban-Bravo G; Garcia-Manero G
    Curr Opin Oncol; 2017 Jan; 29(1):79-87. PubMed ID: 27849645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
    Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
    Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Myelomonocytic Leukemia: Focus on Clinical Practice.
    Patnaik MM; Tefferi A
    Mayo Clin Proc; 2016 Feb; 91(2):259-72. PubMed ID: 26848006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
    Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.
    Singh ZN; Post GR; Kiwan E; Maddox AM
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):293-7. PubMed ID: 21658659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.